Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older

202171 citationsJournal Articlegreen Open Access

Authors

The addition of lenalidomide to R-miniCHOP does not improve OS. Rituximab delivered subcutaneously was safe in this population.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 39, Issue 11, pp. 1203-1213

Field-Weighted Citation Impact: 8.05